AzTrials
AzTrials

Geographic AtrophyPhase 2NCT05019521

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase 2 study testing Danicopan in people with Geographic Atrophy, run by Alexion Pharmaceuticals, Inc. at 128 sites in 13 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. Read more about this study

Who is it for?
Ages 60 years and older
Conditions the study is for
Geographic Atrophy
What is being tested?
Danicopan
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
365 participants
Where
128 sitesin 13 countries
Study dates
23 Aug 2021to 21 Jan 2025
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Vaccination for Neisseria meningitidis.
  • Capable of giving signed informed consent.
  • Presentation of GA secondary to AMD in at least 1 eye
  • The entire GA lesion must be > 1 μm outside of the foveal center

Who cannot join

  • GA in the study eye due to cause other than AMD.
  • Have previously received intravitreal anti-vascular endothelial growth factor injections in study eye for intraocular vascular disease.
  • Have previously received any stem cell/gene therapy for any ophthalmological condition in either eye.
  • Use of any investigational medicinal product (ie, participation in interventional clinical studies for any ophthalmic indications) or use of any regulatory approved treatment for GA in the study eye regardless of route of administration within the last 3 months or 5 half-lives of the last dose of the investigational or commercial product (whichever is longer).
  • Presence of active ocular diseases in the study eye that in the opinion of the Investigator compromises or confounds visual function or interferes with study assessments.
  • Known or suspected complement deficiency.
Show all 9Show fewer
  • History or presence of any medical or psychological condition that, in the opinion of the Principal Investigator, would make the patient inappropriate for the study.
  • Hypersensitivity to fluorescein sodium for injection, the investigational drug (danicopan) or any of its excipients.
  • Note: Additional inclusion/exclusion criteria may apply, per protocol.

Trial locations and contacts

128 sites in 13 countries.

128 sites in 13 countries

United States49 sites
  • Research Site

    Augusta, Georgia, 30909

  • Research Site

    Austin, Texas, 78750

  • Research Site

    Bellaire, Texas, 77401

  • Research Site

    Beverly Hills, California, 90211

  • Research Site

    Cincinnati, Ohio, 45219

  • Research Site

    Clearwater, Florida, 33761

  • Research Site

    Colorado Springs, Colorado, 80909

  • Research Site

    Conroe, Texas, 77384

  • Research Site

    Coral Springs, Florida, 33067

  • Research Site

    Dallas, Texas, 75231

  • Research Site

    Deerfield Beach, Florida, 33064

  • Research Site

    Durham, North Carolina, 27705

  • Research Site

    Encino, California, 91436

  • Research Site

    Fairfax, Virginia, 22031

  • Research Site

    Fresno, California, 93720

  • Research Site

    Fullerton, California, 92835

  • Research Site

    Great Neck, New York, 11021

  • Research Site

    Greenville, South Carolina, 29605

  • Research Site

    Hagerstown, Maryland, 21740

  • Research Site

    Kingston, Pennsylvania, 18704

  • Research Site

    La Jolla, California, 92093

  • Research Site

    Ladson, South Carolina, 29456

  • Research Site

    Longmont, Colorado, 80503

  • Research Site

    Lynchburg, Virginia, 24502

  • Research Site

    Monroeville, Pennsylvania, 15146

  • Research Site

    Naples, Florida, 34103

  • Research Site

    New Albany, Indiana, 47150

  • Research Site

    Palm Beach Gardens, Florida, 33418

  • Research Site

    Pasadena, California, 91105

  • Research Site

    Philadelphia, Pennsylvania, 19104-2640

  • Research Site

    Philadelphia, Pennsylvania, 19107

  • Research Site

    Phoenix, Arizona, 85020

  • Research Site

    Portland, Oregon, 97225

  • Research Site

    Rapid City, South Dakota, 57701

  • Research Site

    Reno, Nevada, 89502

  • Research Site

    Rosedale, Maryland, 21237

  • Research Site

    Sacramento, California, 95841

  • Research Site

    San Antonio, Texas, 78240

  • Research Site

    San Mateo, California, 94401

  • Research Site

    Southaven, Mississippi, 38671

  • Research Site

    Southlake, Texas, 76092

  • Research Site

    Springfield, Massachusetts, 01107

  • Research Site

    Springfield, Oregon, 97477

  • Research Site

    St. Petersburg, Florida, 33711

  • Research Site

    Teaneck, New Jersey, 07666

  • Research Site

    Towson, Maryland, 21204

  • Research Site

    Walnut Creek, California, 94598

  • Research Site

    Waterford, Connecticut, 06385

  • Research Site

    West Des Moines, Iowa, 50266

Other trials in United States

Germany17 sites
  • Research Site

    Berlin, 12203

  • Research Site

    Bonn, 53127

  • Research Site

    Düsseldorf, 40225

  • Research Site

    Freiburg im Breisgau, 79106

  • Research Site

    Göttingen, 37075

  • Research Site

    Hanover, 30625

  • Research Site

    Heidelberg, 69120

  • Research Site

    Mainz A. Rhein, 55131

  • Research Site

    Marburg, 35043

  • Research Site

    München, 81675

  • Research Site

    Münster, 48145

  • Research Site

    Münster, 48149

  • Research Site

    Neubrandenburg, 17036

  • Research Site

    Regensburg, 93053

  • Research Site

    Tübingen, 72076

  • Research Site

    Ulm, 89081

  • Research Site

    Würzburg, 97080

Other trials in Germany

France11 sites
  • Research Site

    Créteil, 94010

  • Research Site

    Écully, 69130

  • Research Site

    Lyon, 69004

  • Research Site

    Marseille, 13008

  • Research Site

    Nantes, 44000

  • Research Site

    Nice, 06000

  • Research Site

    Paris, 75010

  • Research Site

    Paris, 75019

  • Research Site

    Paris, 75571

  • Research Site

    Poitiers, 86021

  • Research Site

    Strasbourg, 67091

Other trials in France

Spain11 sites
  • Research Site

    Barcelona, 08022

  • Research Site

    Barcelona, 08035

  • Research Site

    Barcelona, 8025

  • Research Site

    Bilbao, 48006

  • Research Site

    Córdoba, 14012

  • Research Site

    Majadahonda, 28222

  • Research Site

    Pamplona, 31005

  • Research Site

    Seville, 41071

  • Research Site

    Valencia, 46014

  • Research Site

    Valladolid, 46012

  • Research Site

    Zaragoza, 50009

Other trials in Spain

Italy8 sites
  • Research Site

    Florence, 50134

  • Research Site

    Genova, 16132

  • Research Site

    Milan, 20122

  • Research Site

    Milan, 20132

  • Research Site

    Milan, 20157

  • Research Site

    Naples, 80131

  • Research Site

    Roma, 00133

  • Research Site

    Roma, 00168

Other trials in Italy

United Kingdom8 sites
  • Research Site

    Bristol, BS1 2LX

  • Research Site

    Liverpool, L69 3BX

  • Research Site

    London, EC1V 2PD

  • Research Site

    London, GU16 7UJ

  • Research Site

    London, NW1 5QH

  • Research Site

    London, SE5 9RS

  • Research Site

    Newcastle upon Tyne, NE7 7DN

  • Research Site

    Southampton, S016 6YD

Other trials in United Kingdom

Australia7 sites
  • Research Site

    Adelaide, 5000

  • Research Site

    Albury, 2640

  • Research Site

    East Melbourne, 3002

  • Research Site

    Hurstville, 2220

  • Research Site

    Parramatta, 2150

  • Research Site

    Strathfield, 2135

  • Research Site

    Sydney, 2000

Other trials in Australia

South Korea6 sites
  • Research Site

    Busan, 49241

  • Research Site

    Daegu, 42415

  • Research Site

    Incheon, 22332

  • Research Site

    Jinju, 52727

  • Research Site

    Seoul, 03082

  • Research Site

    Seoul, 06351

Other trials in South Korea

Japan3 sites
  • Research Site

    Fukushima, 960-1295

  • Research Site

    Kita-gun, 761-0793

  • Research Site

    Osaka, 5458586

Other trials in Japan

Czechia2 sites
  • Research Site

    Pardubice, 530 02

  • Research Site

    Prague, 150 00

Other trials in Czechia

Hungary2 sites
  • Research Site

    Budapest, 1133

  • Research Site

    Pécs, 7621

Other trials in Hungary

Latvia2 sites
  • Research Site

    Riga, LV-1009

  • Research Site

    Riga, LV1002

Other trials in Latvia

Slovakia2 sites
  • Research Site

    Bratislava, 811 08

  • Research Site

    Žilina, 012 07

Other trials in Slovakia

About this study

Official title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

Being tested
Danicopan, Placebo
Keywords
Geographic Atrophy, GA, Danicopan, ALXN2040, Complement Inhibition, AMD
Medical subject headings
Geographic Atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DanicopanDrug

    Also called ALXN2040

    Oral tablet.

  • PlaceboDrug

    Oral tablet.

Study groups in NCT05019521
Study groupRoleWhat they receive
Danicopan: 100 mgExperimentalParticipants will receive danicopan 100 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
Receives: Drug: Danicopan
Danicopan: 200 mgExperimentalParticipants will receive danicopan 200 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
Receives: Drug: Danicopan
Danicopan: 400 mgExperimentalParticipants will receive danicopan 400 mg qd during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
Receives: Drug: Danicopan
PlaceboPlacebo comparatorParticipants will receive matching placebo and will be re-randomized to one of the active treatment groups at Week 52, or to the optimal dose, if already identified.
Receives: Drug: Danicopan; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF)

    FAF provides high-contrast retinal images particularly valuable for the detection of atrophic areas. FAF images of the study eye were taken and sent to the reading center for total GA lesion area measurement. The total GA lesion area (square millimeter [mm^2]) was transformed into sqrt (millimeter [mm]). Greater area affected means a worse outcome than smaller area affected. The rate of change from Baseline (mm/year) for each treatment group was estimated based on the coefficients for time and the interaction of time and treatment from the mixed models for repeated measures (MMRM). MMRM analysis included the change from Baseline at post-baseline visit in the sqrt GA lesion area as dependent variable.

    Measured: Baseline, Week 52

Secondary outcomes (28)
  1. Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF

    FAF provides high-contrast retinal images particularly valuable for the detection of atrophic areas. FAF images of the study eye were taken and sent to the reading center for total GA lesion area measurement. The total GA lesion area (mm^2) was transformed into sqrt (mm). Greater area affected means a worse outcome than smaller area affected.

    Measured: Baseline, Week 104

  2. Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF

    FAF provides high-contrast retinal images particularly valuable for the detection of atrophic areas. FAF images of the study eye were taken and sent to the reading center for total GA lesion area (mm^2) measurement. Greater area affected means a worse outcome than smaller area affected.

    Measured: Baseline, Week 52 and Week 104

  3. Change From Baseline to Week 52 and Week 104 in Percent Macular Ellipsoid Zone (EZ) Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by Spectral-domain Optical Coherence Tomography (SD-OCT)

    Photoreceptor loss was assessed by measuring the percent of macular EZ total attenuation using SD-OCT. The EZ was considered to be formed mainly by mitochondria within the ellipsoid layer of the outer portion of the inner segments of the photoreceptors. In SD-OCT, decreases in the integrity and intensity of the EZ have been correlated with the reduction in cone photoreceptors and retinal sensitivity in retinal degenerative diseases. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.

    Measured: Baseline, Week 52 and Week 104

  4. Change From Baseline to Week 52 and Week 104 in Percent Macular EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    Photoreceptor degradation was assessed by measuring the percent of macular EZ partial attenuation using SD-OCT. The EZ was considered to be formed mainly by mitochondria within the ellipsoid layer of the outer portion of the inner segments of the photoreceptors. In SD-OCT, decreases in the integrity and intensity of the EZ have been correlated with the reduction in cone photoreceptors and retinal sensitivity in retinal degenerative diseases. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.

    Measured: Baseline, Week 52 and Week 104

  5. Change From Baseline to Week 52 and Week 104 in Outer Nuclear Layer (ONL) - Retinal Pigment Epithelium (RPE) Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The ONL - RPE mean central 1 mm subfield thickness refers to the average thickness of the retinal layers between the ONL and RPE measured within a 1 mm radius from the foveal center (the central point of the retina).

    Measured: Baseline, Week 52 and Week 104

  6. Change From Baseline to Week 52 and Week 104 in ONL-RPE Mean Central Macular 2 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The ONL - RPE mean central macular 2 mm subfield thickness refers to the thickness of the retina in the central part of the macula, specifically within a 2 mm radius.

    Measured: Baseline, Week 52 and Week 104

  7. Change From Baseline to Week 52 and Week 104 in Ellipsoid Zone (EZ) - (RPE) Macular Volume in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The EZ - RPE macular volume refers to the volume of the retinal tissue between the EZ and the RPE, specifically within the macular region. Changes in EZ-RPE volume indicate the presence or progression of diseases affecting the outer retina.

    Measured: Baseline, Week 52 and Week 104

  8. Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The EZ - RPE mean central 1 mm subfield thickness is a measurement of the thickness of the ellipsoid zone, a layer within the retina, in the central 1 mm region. Changes in EZ-RPE thickness indicate damage or dysfunction within the photoreceptors, which is associated with various eye diseases like AMD.

    Measured: Baseline, Week 52 and Week 104

  9. Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central Macular 2 mm Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The EZ - RPE mean central macular 2 mm thickness measurement reflects the distance between the outer border of the EZ and the inner border of the RPE layer, typically within a central 2 mm area. Decreased EZ-RPE thickness is an early indicator of disease, such as in dry AMD, where a thinning or loss of the EZ is a hallmark. Changes in EZ-RPE thickness is used to monitor treatment response in conditions like AMD.

    Measured: Baseline, Week 52 and Week 104

  10. Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The percentage of total attenuation of the EZ in the central 1 mm subfield is reported.

    Measured: Baseline, Week 52 and Week 104

  11. Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The percentage of partial attenuation of the EZ in the central 1 mm subfield is reported.

    Measured: Baseline, Week 52 and Week 104

  12. Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The percentage of total attenuation of the EZ in the central macular 2 mm subfield is reported.

    Measured: Baseline, Week 52 and Week 104

  13. Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT

    The percentage of partial attenuation of the EZ in the central macular 2 mm subfield is reported.

    Measured: Baseline, Week 52 and Week 104

  14. Change From Baseline to Week 52 and Week 104 in Sub-RPE Central 1 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT

    Sub-RPE compartment measures reflect the disease burden between the RPE and Bruch's membrane. The sub-RPE central 1 mm mean thickness refers to the average thickness of the retina within a 1-mm diameter circular area centered around the fovea (the central part of the retina).

    Measured: Baseline, Week 52 and Week 104

  15. Change From Baseline to Week 52 and Week 104 in Sub-RPE Central Macular 2 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT

    Sub-RPE compartment measures reflect the disease burden between the RPE and Bruch's membrane. The sub-RPE central macular 2 mm subfield thickness refers to the thickness of the retina within a 2-mm radius in the central part of the macula.

    Measured: Baseline, Week 52 and Week 104

  16. Change From Baseline to Week 52 and Week 104 in Panmacular Sub-RPE Volume in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT

    Sub-RPE compartment measures reflect the disease burden between the RPE and Bruch's membrane. The panmacular sub-RPE volume refers to the total volume of fluid or space located underneath the RPE across the entire macula (the central part of the retina).

    Measured: Baseline, Week 52 and Week 104

  17. Change From Baseline to Week 52 and Week 104 in Percent Macular Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT

    Macular total RPE attenuation refers to the degree of thinning or loss of the RPE in the macula, the central part of the retina responsible for sharp, detailed vision. This was measured as a percentage of the macular area affected.

    Measured: Baseline, Week 52 and Week 104

  18. Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT

    The percentage of total attenuation of the RPE in the central 1 mm subfield is reported.

    Measured: Baseline, Week 52 and Week 104

  19. Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT

    The percentage of total attenuation of the RPE in the central macular 2 mm subfield is reported.

    Measured: Baseline, Week 52 and Week 104

  20. Change From Baseline to Week 52 and Week 104 in Monocular Best-corrected Visual Acuity (BCVA) Scores in the Study Eye as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart

    ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

    Measured: Baseline, Week 52 and Week 104

  21. Change From Baseline to Week 52 and Week 104 in Monocular Low Luminance Visual Acuity (LLVA) Scores in the Study Eye as Assessed by the ETDRS Chart

    LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. LLVA was reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Change from baseline: a negative score indicates decline in LLVA.

    Measured: Baseline, Week 52 and Week 104

  22. Change From Baseline to Week 52 and Week 104 in Low Luminance Deficit (LLD) (BCVA-LLVA) Score in the Study Eye

    LLD score was calculated as the difference between BCVA and LLVA (BCVA-LLVA) scores. BCVA and LLVA were reported as the number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision. LLD is a measure of visual acuity impairment in low-light conditions. A higher LLD score indicates a greater difference between vision in bright and dim light, suggesting a more significant loss of visual function in low-luminance settings.

    Measured: Baseline, Week 52 and Week 104

  23. Change From Baseline to Week 52 And Week 104 in Monocular Reading Speeds in the Study Eye as Assessed by Minnesota Low Vision Reading Test (MNRead) Acuity Charts or Radner Reading Charts

    MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the monocular reading speed; disease worsening.

    Measured: Baseline, Week 52 and Week 104

  24. Change From Baseline to Week 52 and Week 104 in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) Composite Scores

    The NEI VFQ-25 instrument measures dimensions of self-reported vision-targeted health status of individuals with chronic eye conditions. The NEI VFQ-25 consists of 11 vision related domains: global vision rating, difficulty with near vision activities, difficulty with distance vision activities, limitations in social function related to vision, role limitations, dependency on others due to vision, mental health symptoms due to vision, driving difficulties, limitations with peripheral- and color-vision, and ocular pain. The NEI VFQ-25 also includes a single item measuring general health. A composite score averages the vision related domains and ranges from 0 (worse) to 100 (best). A higher score represents better functioning. A negative change from baseline indicates a decrease in the visual functioning; disease worsening.

    Measured: Baseline, Week 52 and Week 104

  25. Plasma Concentration of Danicopan

    All values below the limit of quantification (<0.1 nanograms [ng]/milliliter [mL]) were set to 0 for calculation of summary statistics.

    Measured: Day 1 and Week 52

  26. Change From Baseline in Ex Vivo Serum Alternative Pathway (AP) Activity

    Serum AP functional activity was measured by the Wieslab functional immunoassay method.

    Measured: Week 52 (pre-dose, 2 hours post-dose)

  27. Change From Baseline in Plasma Bb Fragment of Complement Factor B (Bb) Concentration

    Measured: Baseline, Week 52 (pre-dose)

  28. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Events Leading To Discontinuation of Study Drug Throughout the Study

    An adverse event (AE) was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), or an important medical event or reaction. A TEAE was defined as any AE that started during or after the first dose of study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Measured: Day 1 through Week 108

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2021
  2. Study start23 Aug 2021
  3. Primary completion5 Jul 2024
  4. Study completion21 Jan 2025

Why it stopped: Lack of efficacy.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
365 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05019521
Sponsor's protocol ID
ALXN2040-GA-201
Other IDs
2021-001198-22
Status last verified
Aug 2025
First submitted
19 Aug 2021
Last updated
5 Sep 2025
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3.

    PubMed 37314061

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Danicopan in people with Geographic Atrophy, run by Alexion Pharmaceuticals, Inc. at 128 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 128 sites in United States, Germany, France, Spain, Italy and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Sep 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF) (time frame: Baseline, Week 52). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05019521, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in